Vincristine placebo

DRUG2 trials

Conditions

Diffuse Large B-Cell LymphomaPreviously Untreated Diffuse large B-cell lymphoma (DLBCL)

Phase 3

A Study Comparing the Efficacy and Safety of Polatuzumab Vedotin With Rituximab-Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Diffuse Large B-Cell Lymphoma

Active, not recruitingNCT03274492

Hoffmann-La RocheDiffuse Large B-Cell Lymphoma

Start: 2017-11-16End: 2026-04-30Updated: 2026-02-06

A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL COMPARING THE EFFICACY AND SAFETY OF POLATUZUMAB VEDOTIN IN COMBINATION WITH RITUXIMAB AND CHP (R-CHP) VERSUS RITUXIMAB AND CHOP (R-CHOP) IN PREVIOUSLY UNTREATED PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA

RecruitingCTIS2024-516904-40-00

F. Hoffmann-La Roche AGPreviously Untreated Diffuse large B-cell lymphoma (DLBCL)

Start: 2018-03-27Target: 356Updated: 2025-10-23

2026-01-01

Preliminary analysis of a multicenter study of Pola-R-CHP in untreated Japanese patients with DLBCL (POLASTAR).

2025-12-03

Assessment of the prognostic value of FDG PET-derived markers and responses in POLARIX

Blood2025-11-03

Real-world comparative outcomes of pola-R-CHP versus R-CHOP in patients with diffuse large B-cell lymphoma

Blood2025-11-03

A single-cell co-expression score of MYC and BCL2 identifies high-risk BCR-addicted DLBCL benefiting from polatuzumab vedotin in the POLARIX trial

Blood2025-11-03

Real-world use of Pola-R-CHP for untreated diffuse large B-cell lymphoma (DLBCL): A systematic literature review

Blood2025-11-03

Transcriptional profiling refines DLBCL classification and identifies subtypes with distinct therapeutic vulnerabilities

Blood2025-11-03

Five-Year Outcomes of the POLARIX Study Comparing Pola-R-CHP and R-CHOP in Patients With Diffuse Large B-Cell Lymphoma

Journal of Clinical Oncology2025-09-249 citations

Subgroup analysis of older patients ≥60 years with diffuse large B-cell lymphoma in the phase 3 POLARIX study

Blood Advances2025-03-145 citations

Mosunetuzumab plus Pola-CHP compared with Pola-R-CHP in previously untreated DLBCL: final results from a phase 2 study

Blood Advances2025-02-056 citations

Is first-line treatment with polatuzumab vedotin–rituximab–cyclophosphamide, doxorubicin and prednisone (pola-R-CHP) for previously untreated diffuse large B-cell lymphoma cost-effective in China? A cost-effectiveness analysis using a Markov model

BMJ Open2025-01-012 citations

Five-Year Analysis of the POLARIX Study: Prolonged Follow-up Confirms Positive Impact of Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-R-CHP) on Outcomes

Blood2024-11-0517 citations

A Multicenter, Prospective, Observational Study of Pola-R-CHP in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (POLASTAR): A Preliminary Analysis

Blood2024-11-052 citations

Genomic profiling in a subgroup analysis of patients (pts) with diffuse large B-cell lymphoma (DLBCL) and extranodal (EN) sites of involvement in the phase 3 Pola-R-CHP versus R-CHOP (POLARIX) study.

Journal of Clinical Oncology2024-06-01

Population pharmacokinetics and exposure–response analyses of polatuzumab vedotin in patients with previously untreated <scp>DLBCL</scp> from the <scp>POLARIX</scp> study

CPT Pharmacometrics & Systems Pharmacology2024-04-154 citations

Deciphering the Clinical Benefit of Pola-R-CHP versus R-CHOP in Different Genetic Subtypes Beyond Cell of Origin in the POLARIX Study

Blood2023-11-0221 citations

Plasma Circulating Tumor DNA (ctDNA) as an Alternative to Tissue DNA for Genotyping of DLBCL: Results from the POLARIX Study

Blood2023-11-023 citations

Ethnic sensitivity assessment: Polatuzumab vedotin pharmacokinetics in Asian and non‐Asian patients with previously untreated diffuse large B‐cell lymphoma in POLARIX

Clinical and Translational Science2023-10-215 citations

Treatment Efficacy & Safety in Elderly Patients With DLBCL

Oncology Times2023-07-05

Circulating tumor DNA (ctDNA) status and clinical outcomes in patients (pts) with previously untreated diffuse large B-cell lymphoma (DLBCL) in the POLARIX study.

Journal of Clinical Oncology2023-06-014 citations

33 more papers not shown

Vincristine placebo

Sponsors

Conditions

Phase 3

Related Papers